Your browser is no longer supported. Please, upgrade your browser.
Enochian Biosciences, Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own61.79% Shs Outstand52.22M Perf Week-14.94%
Market Cap599.53M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float20.33M Perf Month-1.68%
Income-34.70M PEG- EPS next Q- Inst Own2.90% Short Float3.43% Perf Quarter20.36%
Sales- P/S- EPS this Y-129.90% Inst Trans-38.13% Short Ratio3.21 Perf Half Y111.31%
Book/sh3.20 P/B2.92 EPS next Y- ROA-19.30% Target Price- Perf Year223.18%
Cash/sh0.24 P/C38.93 EPS next 5Y- ROE-20.90% 52W Range2.80 - 13.78 Perf YTD216.61%
Dividend- P/FCF- EPS past 5Y-25.50% ROI- 52W High-32.22% Beta0.59
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin- 52W Low233.57% ATR0.98
Employees11 Current Ratio12.80 Sales Q/Q- Oper. Margin- RSI (14)44.11 Volatility14.99% 9.01%
OptionableYes Debt/Eq0.00 EPS Q/Q-287.80% Profit Margin- Rel Volume2.12 Prev Close11.48
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume217.41K Price9.34
Recom- SMA20-11.01% SMA504.05% SMA20060.46% Volume461,758 Change-18.64%
Dec-03-21 07:00AM  
Oct-18-21 07:00AM  
Oct-15-21 06:00PM  
Oct-12-21 06:00PM  
Sep-27-21 07:00AM  
Sep-26-21 10:42AM  
Sep-13-21 07:00AM  
Aug-30-21 07:00AM  
Aug-23-21 10:18AM  
Jul-20-21 07:00AM  
Jul-12-21 08:37AM  
Jun-30-21 07:00AM  
Jun-21-21 05:31PM  
Jun-15-21 09:05AM  
Jun-14-21 03:15PM  
May-12-21 04:29PM  
Apr-30-21 03:42AM  
Mar-24-21 06:00PM  
Feb-22-21 05:15PM  
Nov-01-20 09:35AM  
Sep-10-20 12:50AM  
Jul-27-20 08:00AM  
Jun-08-20 07:30AM  
May-14-20 09:50AM  
May-13-20 08:00AM  
Apr-23-20 07:00AM  
Apr-09-20 10:00AM  
Feb-24-20 07:30AM  
Feb-03-20 07:30AM  
Jan-06-20 07:30AM  
Dec-10-19 07:00AM  
Nov-25-19 07:00AM  
Nov-21-19 10:30AM  
Oct-31-19 04:17PM  
Oct-26-19 10:18AM  
Jun-03-19 07:00AM  
Apr-29-19 09:19AM  
Mar-07-19 12:45PM  
Feb-01-19 02:31PM  
Jan-16-19 04:00PM  
Jan-07-19 08:30AM  
Jan-04-19 08:00AM  
Dec-05-18 08:30AM  
Dec-03-18 08:30AM  
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.